112077-95-9

Upstream product

• 100-01-6 4-nitro-aniline 
• 4850-93-5 N-(4-nitrophenyl)propionamide 
• 90918-78-8 N-methyl-N-(4-nitrophenyl)propionamide 

Downstream Products

• 1254783-85-1 N-(4-(6-(1-acryloylpiperidin-3-ylamino)-9H-purin-2-ylamino)phenyl)-N-methylpropionamide 
• 1254782-72-3 C₂₄H₃₀N₈O₂ 
• 1254783-89-5 N-methyI-N-(4-(6-(piperidin-3-ylamino)-9H-purin-2-ylamino)phenyl)propionamide 
• 1254783-88-4 tert-butyl-3-(2-(4-(N-methylpropionamido)phenylamino)-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-ylamino)piperidine-1-carboxylate 

Relevant academic research and scientific papers

Discovery of selective irreversible inhibitors for EGFR-T790M

Targeting the epidermal growth factor receptor kinase (EGFR) with ATP-competitive kinase inhibitors results in dramatic but short-lived responses in patients with EGFR mutant non small cell lung cancer. A series of novel covalent EGFR kinase inhibitors with selectivity for the clinically relevant T790M 'gatekeeper' resistance mutation relative to wild-type EGFR were discovered by library screening. A representative compound 3i was obtained through a systematic SAR study guided by mutant EGFR-dependent cellular proliferation assays.

EGFR INHIBITORS AND METHODS OF TREATING DISORDERS

The present invention relates to novel pyrimidine, pyrrolo-pyrimidine, pyrrolo-pyridine, pyridine, purine and triazine compounds which are able to modulate epidermal growth factor receptor (EGFR), including Her-kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.

Purine derivatives inhibitors of tyrosine protein kinase SYK

Disclosed are compounds of the formula in free or salt form, wherein X, R1, R2, R3, and R4are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment o